1mon
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled ...
The U.S. Food and Drug Administration (FDA) selected glucose monitoring company Dexcom as the first participant in its Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices ...
People with diabetes can use continuous glucose monitors (CGMs) to make tracking their blood sugar levels easier. Instead of drawing blood multiple times per day, a person continuously wears a sensor ...
Participation advances the company’s vision and regulatory pathway for earlier intervention, screening for prediabetes and Type 2 diabetes and empowerment Dexcom (NASDAQ: DXCM), the global leader in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results